MedXPrime Revenue and Competitors
Estimated Revenue & Valuation
- MedXPrime's estimated annual revenue is currently $4M per year.
- MedXPrime's estimated revenue per employee is $175,000
Employee Data
- MedXPrime has 23 Employees.
- MedXPrime grew their employee count by -48% last year.
MedXPrime's People
Name | Title | Email/Phone |
---|---|---|
1 | CEO | Reveal Email/Phone |
2 | Associate Director Client Services | Reveal Email/Phone |
MedXPrime Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $8.6M | 43 | 5% | N/A | N/A |
#2 | $59.7M | 217 | 6% | N/A | N/A |
#3 | $6.2M | 31 | 7% | N/A | N/A |
#4 | $24M | 96 | 20% | N/A | N/A |
#5 | $20.3M | 81 | 4% | N/A | N/A |
#6 | $9M | 45 | 7% | N/A | N/A |
#7 | $26.3M | 105 | 25% | N/A | N/A |
#8 | $16.4M | 73 | 7% | N/A | N/A |
#9 | $2.3M | 15 | 7% | N/A | N/A |
#10 | $30.5M | 122 | -14% | N/A | N/A |
What Is MedXPrime?
Tomorrow's medicine, today. Increasing the safety and efficacy of prescription drug therapy with pharmacogenetic testing. The era of ‘Personalized Medicine’ has now come. It allows your physician to understand from your specific DNA profile what medications will work best. It’s called ‘pharmacogenetic testing’ or PGT. No more trial and error prescribing, no longer having the danger of Adverse Drug Reactions (ADRs) which put over 2 million people annually in the hospital and cause over 100,000 deaths each year. Now doctors can have the knowledge to avoid these issues. Personalized Medicine helps doctors to individualize drug therapy, decrease adverse drug reactions, and increase the effectiveness of treatment plans. In other words: “Right Information, Right Drug, Right Dose, Right from the beginning".
keywords:N/AN/A
Total Funding
23
Number of Employees
$4M
Revenue (est)
-48%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $2.5M | 25 | 9% | N/A |
#2 | $2.7M | 27 | -10% | N/A |
#3 | $4.4M | 28 | -18% | N/A |
#4 | $5.9M | 29 | -6% | N/A |
#5 | $2.8M | 29 | N/A | N/A |